131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma

Sponsor
Korea Cancer Center Hospital
Study ID
NCT01678404
Phase
PHASE2
Status
Unknown

Conditions

  • Relapsed or Refractory Marginal Zone B-cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Marginal zone B-cell lymphoma (MZL) is a lymphoma originated from B-cell in lymph node with variable differentiation status, which is distributed to a variety of organs. A high response rate and long term survival is possible through surgery or radiation therapy alone in the case of limited disease. However frequent relapse and progression is observed despite of long term survival. The treatment after relapse has not been established yet. So we investigate the efficacy of radioimmunotherapy using 131I-rituximab in refractory or relapsed patients with MZL.

Key Dates

Start date
Oct 31, 2011
Status verified
Aug 2012
Primary completion
Sep 30, 2014
Completion
Sep 30, 2016

Study Design

Enrollment
28 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 131I-rituximab
    131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles

Primary Outcome Measure

Overall response rate [ Time Frame: up to 5 years ]

Central Contacts